These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

6384 related items for PubMed ID: 15669880

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL, Faulds D.
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep 12; 352(9131):837-53. PubMed ID: 9742976
    [Abstract] [Full Text] [Related]

  • 26. New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.
    Braunstein S.
    Clin Ther; 2003 Jul 12; 25(7):1895-917. PubMed ID: 12946541
    [Abstract] [Full Text] [Related]

  • 27. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P.
    Diabetes Technol Ther; 2012 Jun 12; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J, Caputo S, Damci T, Orozco-Beltran D, Pan C, Svendsen AL, Sølje KS, Khunti K, SOLVE study group.
    J Clin Pharm Ther; 2014 Apr 12; 39(2):136-43. PubMed ID: 24329524
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The role of sulphonylureas in the management of type 2 diabetes mellitus.
    Rendell M.
    Drugs; 2004 Apr 12; 64(12):1339-58. PubMed ID: 15200348
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
    Lebovitz HE.
    Drugs; 1992 Apr 12; 44 Suppl 3():21-8. PubMed ID: 1280574
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.
    Scheen AJ.
    Drug Saf; 2005 Jul 12; 28(7):601-631. PubMed ID: 27722966
    [Abstract] [Full Text] [Related]

  • 37. Type II diabetes mellitus.
    Edelman SV.
    Adv Intern Med; 1998 Jul 12; 43():449-500. PubMed ID: 9506190
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
    Purnell JQ, Weyer C.
    Treat Endocrinol; 2003 Jul 12; 2(1):33-47. PubMed ID: 15871553
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 320.